Novo Nordisk executives project that oral pills could capture more than a third of the total obesity drug market by 2030. Photo: Reuters
5 min read . 07:00 am IST
Novo Nordisk and Eli Lilly have dominated the market until now, but this year is set to bring oral drugs, generics, and a fight for global dominance.















